Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.47 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 11/20 | 0.41 |
| ▸ | AURKA | O14965 | 10/20 | 0.41 |
| ▸ | TTK | P33981 | 9/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 9/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618186 | 0.81 | — | — | |
| SCHEMBL4257130 | 0.81 | — | — | |
| SCHEMBL620683 | 0.66 | — | — | |
| SCHEMBL7571334 | 0.61 | — | — | |
| SCHEMBL8150851 | 0.61 | — | — | |
| SCHEMBL15618232 | 0.61 | HTT (0.52) | AURKBAURKAMAPTHTTKMT2A | |
| SCHEMBL621291 | 0.61 | — | — | |
| SCHEMBL202631 | 0.61 | — | — | |
| SCHEMBL1038352 | 0.61 | — | — | |
| SCHEMBL13514472 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041033-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MUNOZ JULIO A (US) | 2012-02-16 | — | — | US | disclosed |
| US-8053451-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| EP-2371818-A1 | Hydroxybenzoate salts of metanicotine compounds | Targacept, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041033-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | ERCC1 3294/4885ERCC4 2324/4885AURKB 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.